Brain-controlled Spinal Cord Stimulation in Patients With Spinal Cord Injury
STIMO-BSI
1 other identifier
interventional
3
1 country
1
Brief Summary
In a current first-in-human study, called Stimulation Movement Overground (STIMO, NCT02936453), Epidural Electrical Stimulation (EES) of the spinal cord is applied to enable individuals with chronic severe spinal cord injury (SCI) to complete intensive locomotor neurorehabilitation training. In this clinical feasibility study, it was demonstrated that EES results in an immediate enhancement of walking function, and that when applied repeatedly as part of a neurorehabilitation program, EES can improve leg motor control and trigger neurological recovery in individuals with severe SCI to a certain extent (Wagner et al. 2018). Preclinical studies showed that linking brain activity to the onset and modulation of spinal cord stimulation protocols not only improves the usability of the stimulation, but also augments neurological recovery. Indeed, rats rapidly learned to modulate their cortical activity in order to adjust the amplitude of spinal cord stimulation protocols. This brain-spine interface allowed them to increase the amplitude of the movement of their otherwise paralyzed legs to climb up a staircase (Bonizzato et al. 2018). Moreover, gait rehabilitation enabled by this brain-spine interface (BSI) augmented plasticity and neurological recovery. When EES was correlated with cortical neuron activity during training, rats showed better recovery than when training was only supported by continuous stimulation (Bonizzato et al. 2018). This concept of brain spine-interface was validated in non-human primates (Capogrosso et al. 2016). Clinatec (Grenoble, France) has developed a fully implantable electrocorticogram (ECoG) recording device with a 64-channel epidural electrode array capable of recording electrical signals from the motor cortex for an extended period of time and with a high signal to noise ratio the electrical signals from the motor cortex. This ECoG-based system allowed tetraplegic patients to control an exoskeleton (ClinicalTrials.gov, NCT02550522) with up to 8 degrees of freedom for the upper limb control (Benabid et al. 2019). This device was implanted in 2 individuals so far; one of them has been using this system both at the hospital and at home for more than 3 years. We hypothesize that ECoG-controlled EES in individuals with SCI will establish a direct bridge between the patient's motor intention and the spinal cord below the lesion, which will not only improve or restore voluntary control of leg movements, but will also boost neuroplasticity and neurological recovery when combined with neurorehabilitation.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable
Started Jul 2021
Longer than P75 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
November 5, 2020
CompletedFirst Posted
Study publicly available on registry
November 17, 2020
CompletedStudy Start
First participant enrolled
July 4, 2021
CompletedPrimary Completion
Last participant's last visit for primary outcome
March 1, 2028
ExpectedStudy Completion
Last participant's last visit for all outcomes
March 1, 2028
June 29, 2025
June 1, 2025
6.7 years
November 5, 2020
June 25, 2025
Conditions
Outcome Measures
Primary Outcomes (2)
Safety Measure
Number of Adverse Events possibly, probably or causally related to the procedure or device.
Through study completion, an average of 1 year
Safety Measure
Number of device deficiencies
Through study completion, an average of 1 year
Secondary Outcomes (16)
WISCI II score
1 week before implantation, 8 weeks and 19 weeks after implantation
10mWT
1 week before implantation, 8 weeks and 19 weeks after implantation
Weight bearing capacity
1 week before implantation, 8 weeks and 19 weeks after implantation
SCIM III score
1 week before implantation, 8 weeks and 19 weeks after implantation
6minWT
1 week before implantation, 8 weeks and 19 weeks after implantation
- +11 more secondary outcomes
Study Arms (1)
All participants
EXPERIMENTALAll participants receive the same intervention.
Interventions
Participants are implanted bilaterally with epidural electrocorticography devices. The decoded motor intentions are driving the implanted spinal cord stimulation system. Brain-controlled spinal cord stimulation is used for training and rehabilitation to recover voluntary movements.
ARC-BSI Lumbar System for participants entering the optional extension with system upgrade: replacement of the neurostimulator, and upgrade of the WIMAGINE system and STIMO system wearable devices.
Eligibility Criteria
You may qualify if:
- Having completed the main phase of the STIMO study (NCT02936453).
- SCI graded as American Spinal Injury Association Impairment Scale (AIS) A, B, C \& D
- Level of lesion: T10 and above, based on AIS level determination by the PI, with preservation of conus function
- The intact distance between the cone and the lesion must be at least 60 mm.
- Focal spinal cord disorder caused by either trauma or epidural, subdural or intramedullary bleeding
- Minimum 12 months post-injury
- Completed in-patient rehabilitation program
- Stable medical, physical and psychological condition as considered by Investigators
- Able to understand and interact with the study team in French or English
- Adequate care-giver support and access to appropriate medical care in patient's home community
- Must agree to comply in good faith with all conditions of the study and to attend all required study training and visit
- Must provide and sign the Informed Consent prior to any study related procedures
You may not qualify if:
- Limitation of walking function based on accompanying (CNS) disorders (systemic malignant disorders, cardiovascular disorders restricting physical training, peripheral nerve disorders)
- History of severe autonomic dysreflexia
- Brain damage
- Epilepsy
- Spinal stenosis
- Use of an intrathecal Baclofen pump.
- Any active implanted cardiac device such as pacemaker or defibrillator.
- Any indication that would require diathermy.
- Any indication that would require MRI.
- Increased risk for defibrillation.
- Severe joint contractures disabling or restricting lower limb movements.
- Haematological disorders with increased risk for surgical interventions (increased risk of haemorrhagic events).
- Congenital or acquired lower limb abnormalities (affection of joints and bone).
- Women who are pregnant (pregnancy test obligatory for women of childbearing potential) or breast feeding or not willing to take contraception.
- Known or suspected non-compliance, drug or alcohol abuse.
- +5 more criteria
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
CHUV
Lausanne, Canton of Vaud, 1011, Switzerland
Related Publications (4)
Wagner FB, Mignardot JB, Le Goff-Mignardot CG, Demesmaeker R, Komi S, Capogrosso M, Rowald A, Seanez I, Caban M, Pirondini E, Vat M, McCracken LA, Heimgartner R, Fodor I, Watrin A, Seguin P, Paoles E, Van Den Keybus K, Eberle G, Schurch B, Pralong E, Becce F, Prior J, Buse N, Buschman R, Neufeld E, Kuster N, Carda S, von Zitzewitz J, Delattre V, Denison T, Lambert H, Minassian K, Bloch J, Courtine G. Targeted neurotechnology restores walking in humans with spinal cord injury. Nature. 2018 Nov;563(7729):65-71. doi: 10.1038/s41586-018-0649-2. Epub 2018 Oct 31.
PMID: 30382197BACKGROUNDCapogrosso M, Milekovic T, Borton D, Wagner F, Moraud EM, Mignardot JB, Buse N, Gandar J, Barraud Q, Xing D, Rey E, Duis S, Jianzhong Y, Ko WK, Li Q, Detemple P, Denison T, Micera S, Bezard E, Bloch J, Courtine G. A brain-spine interface alleviating gait deficits after spinal cord injury in primates. Nature. 2016 Nov 10;539(7628):284-288. doi: 10.1038/nature20118.
PMID: 27830790BACKGROUNDBenabid AL, Costecalde T, Eliseyev A, Charvet G, Verney A, Karakas S, Foerster M, Lambert A, Moriniere B, Abroug N, Schaeffer MC, Moly A, Sauter-Starace F, Ratel D, Moro C, Torres-Martinez N, Langar L, Oddoux M, Polosan M, Pezzani S, Auboiroux V, Aksenova T, Mestais C, Chabardes S. An exoskeleton controlled by an epidural wireless brain-machine interface in a tetraplegic patient: a proof-of-concept demonstration. Lancet Neurol. 2019 Dec;18(12):1112-1122. doi: 10.1016/S1474-4422(19)30321-7. Epub 2019 Oct 3.
PMID: 31587955BACKGROUNDBonizzato M, Pidpruzhnykova G, DiGiovanna J, Shkorbatova P, Pavlova N, Micera S, Courtine G. Brain-controlled modulation of spinal circuits improves recovery from spinal cord injury. Nat Commun. 2018 Aug 1;9(1):3015. doi: 10.1038/s41467-018-05282-6.
PMID: 30068906BACKGROUND
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Jocelyne Bloch
Centre Hospitalier Universitaire Vaudois
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NA
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Prof.
Study Record Dates
First Submitted
November 5, 2020
First Posted
November 17, 2020
Study Start
July 4, 2021
Primary Completion (Estimated)
March 1, 2028
Study Completion (Estimated)
March 1, 2028
Last Updated
June 29, 2025
Record last verified: 2025-06
Data Sharing
- IPD Sharing
- Will not share